Efficacy and Safety Study of Ultra-early Mobile Stroke Unit Neuroprotection Combined With Revascularization for Acute Ischemic Stroke (EXCELLENT)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.
Also called NCT07119021
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 300 participants
- Registry
-
NCT07119021
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07119021. Randomized; quadruple masking; primary purpose prevention. Start 2024-08-01 (actual); primary completion 2027-04-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety Study of Ultra-early Mobile Stroke Unit Neuroprotection Combined With Revascularization for Acute Ischemic Stroke (EXCELLENT)
- Acronym
- EXCELLENT
- Condition
- Ischemic Stroke
- Intervention (Drug)
- Intravenous thrombolysis + edaravone
- Intervention (Drug)
- IV thrombolysis + placebo (control group)
- Lead sponsor
- Ruijun Ji
- Collaborator
- Xing'an League People's Hospital
- Collaborator
- The First Affiliated Hospital of Soochow University
- Collaborator
- Nanyang Nanshi Hospital
- Collaborator
- Nanjing Baixinyu Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct07119021- Content hash
91d7d666242193692e4cb9e3add754b00b43d830ae1544f35863e4db00c97eb6